Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Viatris
(NASDAQ:VTRS)
Intraday
$11.94
0.11
[0.93%]
After-Hours
$11.94
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$11.94
0.11
[0.93%]
At close: Mar 28
$11.94
0
[0.00%]
After Hours: 4:29PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Viatris Stock (NASDAQ:VTRS)
Viatris Stock (NASDAQ: VTRS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
Piper Sandler Reiterates Neutral on Viatris, Raises Price Target to $13
Benzinga Newsdesk
-
5 hours ago
Friday, March 15, 2024
Looking Into Viatris's Recent Short Interest
Benzinga Insights
-
Mar 15, 2024, 9:00AM
Monday, March 11, 2024
Viatris shares are trading lower after the company and Mapi Pharma received a Complete Response Letter from the FDA regarding its NDA for GA Depot 40mg.
Benzinga Newsdesk
-
Mar 11, 2024, 12:29PM
Earlier On Monday, Viatris' Mapi Pharma Received An FDA Complete Response Letter Regarding The New Drug Application For GA Depot 40mg, The Companies Are Reviewing The Content Of The CRL And Will Be Determining The Appropriate Next Steps
Benzinga Newsdesk
-
Mar 11, 2024, 10:55AM
Wednesday, February 28, 2024
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
Piero Cingari
-
Feb 28, 2024, 2:08PM
Viatris shares are trading lower after the company reported worse-than-expected Q4 financial results.
Benzinga Newsdesk
-
Feb 28, 2024, 12:33PM
Viatris Expects Fiscal Year 2024 Adjusted EPS Of $2.70-$2.85 Versus Consensus Of $2.81
Benzinga Newsdesk
-
Feb 28, 2024, 6:36AM
Viatris Expects Fiscal Year 2024 Revenues Of $15.25B-$15.75B Versus Consensus Of $15.19B
Benzinga Newsdesk
-
Feb 28, 2024, 6:35AM
Viatris Q4 Adjusted EPS $0.62 Misses $0.65 Estimate, Sales $3.83B Miss $3.87B Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 6:33AM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments
Nabaparna Bhattacharya
-
Feb 28, 2024, 5:20AM
Viatris And Idorsia Enter Into Significant Global Research And Development Collaboration
Benzinga Newsdesk
-
Feb 28, 2024, 3:12AM
Monday, February 26, 2024
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Feb 26, 2024, 9:44AM
Tuesday, February 06, 2024
UK's CMA Says Launch Of Theramex/Viatris Merger Inquiry By Notice To The Parties
Benzinga Newsdesk
-
Feb 6, 2024, 9:13AM
Tuesday, January 23, 2024
(VTRS) - Analyzing Viatris's Short Interest
Benzinga Insights
-
Jan 23, 2024, 9:00AM
Monday, January 22, 2024
Watching Alight, Inc., Viatris Inc.; Traders Circulating Greenlight Quarterly Letter, David Einhorn Saying He Built New Long Positions In The Companies
Benzinga Newsdesk
-
Jan 22, 2024, 11:15AM
Friday, January 12, 2024
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Priya Nigam
-
Jan 12, 2024, 10:18AM
Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
Avi Kapoor
-
Jan 12, 2024, 8:26AM
Wednesday, January 10, 2024
Viatris shares are trading higher following the company's presentation at the J.P. Morgan Healthcare Conference.
Benzinga Newsdesk
-
Jan 10, 2024, 3:49PM
Watching Viatris; Shares Spike Higher, Co Participating At 42nd Annual J.P. Morgan Healthcare Conference Presentation Followed By A Fireside Chat Scheduled At 1:30 P.M. ET
Benzinga Newsdesk
-
Jan 10, 2024, 2:30PM
Friday, January 05, 2024
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
Vandana Singh
-
Jan 5, 2024, 10:36AM
Wednesday, January 03, 2024
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
Piero Cingari
-
Jan 3, 2024, 10:26AM
Thursday, December 28, 2023
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
Vandana Singh
-
Dec 28, 2023, 8:46AM
Wednesday, December 27, 2023
Regeneron Shares Moving Higher Amid Circulation Of Court Documents Related To Patent Suit With Viatris
Benzinga Newsdesk
-
Dec 27, 2023, 1:49PM
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
Avi Kapoor
-
Dec 27, 2023, 7:42AM
Monday, December 25, 2023
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
-
Dec 25, 2023, 9:43AM
Saturday, December 16, 2023
Viatris Announces The Appointment Of Theodora "Doretta" Mistras As Chief Financial Officer, Effective March 1, 2024, And Philippe Martin As Chief R&D Officer With Immediate Effect
Benzinga Newsdesk
-
Dec 16, 2023, 6:31PM
Wednesday, November 22, 2023
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11
Benzinga Newsdesk
-
Nov 22, 2023, 12:57PM
Monday, November 13, 2023
5 Value Stocks To Watch In The Healthcare Sector
Benzinga Insights
-
Nov 13, 2023, 9:44AM
Tuesday, November 07, 2023
Viatris Revises Full-Year Total Revenues Guidance Range Solely To Reflect The Expected Negative Impact Of Foreign Exchange; Now Sees FY23 Revenue Down From $15.5B-$16B To $15.4B-$15.6B Vs $15.67B Est.
Benzinga Newsdesk
-
Nov 7, 2023, 7:47PM
Recap: Viatris Q3 Earnings
Benzinga Insights
-
Nov 7, 2023, 4:45PM
Viatris Q3 2023 Adj EPS $0.79 Beats $0.74 Estimate, Sales $3.94B Miss $4.02B Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 4:44PM
Viatris Q3 Sales $3.94B Miss $4.02B Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 4:16PM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Monday, October 30, 2023
Theravance Biopharma Said Co's Units, Mylan Ireland Limited & Mylan Specialty L.P. Entered Settlement Deal With Teva Pharmaceuticals, Its Units Regarding Patent Litigation
Charles Gross
-
Oct 30, 2023, 5:25PM
Monday, October 23, 2023
Viatris shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform.
Benzinga Newsdesk
-
Oct 23, 2023, 3:31PM
B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target
Benzinga Newsdesk
-
Oct 23, 2023, 7:21AM
Tuesday, October 03, 2023
Obesity Drug Wegovy's Triumph To Bring $12B To Novo Holdings In Years Ahead: CEO
Vandana Singh
-
Oct 3, 2023, 12:17PM
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Vandana Singh
-
Oct 3, 2023, 10:11AM
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Vandana Singh
-
Oct 3, 2023, 8:32AM
Monday, October 02, 2023
Market-Moving News for October 2nd
Benzinga Newsdesk
-
Oct 2, 2023, 8:48AM
Viatris shares are trading higher after the company announced it plans to sell certain OTC products, its Women's Healthcare business, its Active Pharmaceutical Ingredients business in India and more.
Benzinga Newsdesk
-
Oct 2, 2023, 8:37AM
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Lekha Gupta
-
Oct 2, 2023, 7:50AM
Viatris To Divest OTC, Women's Healthcare, And API Businesses In Strategic Move, For Up To $6.94B Of Total Gross Proceeds
Benzinga Newsdesk
-
Oct 2, 2023, 3:07AM
Thursday, September 28, 2023
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report (UPDATED)
Vandana Singh
-
Sep 28, 2023, 7:44PM
Wednesday, September 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Lisa Levin
-
Sep 27, 2023, 9:03AM
Tuesday, September 26, 2023
Watching Ocuphire Pharma; Note From Canaccord Says 'FDA Approved Ocuphire's Ryzumvi For Reversal Of Mydriasis Ahead Of Schedule (PDUFA Date 09/28). The first $10M Milestone Payment Is Expected From Partner Viatris'
Benzinga Newsdesk
-
Sep 26, 2023, 2:18PM
Friday, September 22, 2023
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
Piero Cingari
-
Sep 22, 2023, 10:46AM
Tuesday, September 05, 2023
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Benzinga Newsdesk
-
Sep 5, 2023, 5:02AM
Monday, August 07, 2023
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Vandana Singh
-
Aug 7, 2023, 11:35AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch